Achaogen and Crystal Bioscience Enter into Collaboration and License Agreement to Identify and Develop Antibodies for Multiple ...
SOUTH SAN FRANCISCO, Calif. and EMERYVILLE, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, …